NDAORALTABLET
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
4/8 — Partial
SEGLENTIS (celecoxib; tramadol hydrochloride) by Kowa Pharmaceuticals is 12. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEGLENTIS is a fixed-dose combination of celecoxib (a selective COX-2 inhibitor) and tramadol hydrochloride (an opioid analgesic) approved for oral use. It provides dual analgesic and anti-inflammatory action through COX-2 inhibition and opioid receptor agonism. The combination targets moderate to severe pain management by synergistic reduction of prostaglandin-mediated pain and inflammatory response.
$0.664MPart D
Peak4.8 years to LOEProduct is at peak lifecycle stage with 2,599 Medicare Part D claims in 2023, indicating a niche but established position with focused commercial infrastructure.
Mechanism of Action
12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Celecoxib has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of…
Worked on SEGLENTIS at Kowa Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.